Clinical trials: Frontotemporal Lobar Degeneration, open to volunteers
PSP - Progressive Supranuclear Palsy
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP.
- Trial name
- NCT07217665
- Testing
- AADvac1
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Adam Boxer
Parkinson Disease, Amyotrophic Lateral Sclerosis (ALS)
Discovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Early Diagnosis, Prognosis and Therapeutic Management of Patients Affected by Neurodegenerative Disorders
Neurodegenerative disorders (NDDs), such as Parkinson¿s disease (PD), Alzheimer¿s disease (AD), Frontotemporal dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS) are characterized by aggregation and intracellular accumulation…
- Conditions
- Parkinson Disease, Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Alzheimer's Disease (AD)
- Trial name
- NCT06803784
- Testing
- Genetic: whole genome sequencing, whole exome sequencing
- Where
- Italy
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Neuromed IRCCS
Alzheimer Disease
Learning Amyloid and Tau Results
This is a prospective, single-cohort, single-center, observational study to assess if learning one's Alzheimer's disease biomarker test result impacts longitudinal psychosocial, behavioral, and neuropsychological outcomes, and to…
- Trial name
- NCT07222930
- Testing
- Disclose amyloid, tau results, Follow-up Assessments
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Alzheimer's Disease (AD), Frontotemporal Dementia (FTD)
Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence Models
This multicenter study aims to characterize the language profiles of patients with various neurodegenerative diseases, including Alzheimer's disease (AD), Primary Progressive Aphasia (PPA), behavioral variant Frontotemporal…
- Conditions
- Alzheimer's Disease (AD), Frontotemporal Dementia (FTD), Parkinsons Disease (PD), Lewy Body Dementia
- Trial name
- AILAN (NCT07906769)
- Testing
- Speech and language Test to support clinical diagnosis
- Where
- Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Dementia, Frontotemporal, Alzheimer Dementia (AD)
Investigating Genetic Status in Patients Presenting to Clinic
The causes of neurodegenerative dementias such as Frontotemporal Dementia, Lewy Body Disease and Alzheimer's disease are still largely unknown.
- Conditions
- Dementia, Frontotemporal, Alzheimer Dementia (AD), Lewy Body Dementia (LBD)
- Trial name
- NCT05911932
- Testing
- Biosample collection.
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Primary Progressive Aphasia(PPA), Semantic Dementia
Intervention for Communication Quality of Life in Primary Progressive Aphasia
The goal of this clinical trial is to learn whether a personalized, multi-component, virtual speech language treatment program can improve communication and quality of life for adults with primary progressive aphasia (PPA) and…
- Conditions
- Primary Progressive Aphasia(PPA), Semantic Dementia, Logopenic Progressive Aphasia (LPA), Nonfluent Aphasia, Progressive
- Trial name
- Multi-PA (NCT07219680)
- Testing
- Multicomponent Lexical Retrieval Cascade Training, Multicomponent Video Implemented Script Training in Aphasia
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Maya Henry
Tauopathies
Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 18F-JSS20-183A. The goal of this radiotracer is to quantify 4Repeat Tau (4Rtau) protein that is abnormally deposited in the brain…
- Trial name
- NCT06932809
- Testing
- 18F-JSS20-183A PET, Brain MRI, Amyloid PET
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- University of Pennsylvania
Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS)
[18F]ACI-19626 PET in TDP-43 Proteinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein TDP-43 [involved in rare forms of dementia such as frontotemporal dementia (FTD) and in amyotrophic…
- Conditions
- Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), TDP-43 Proteinopathies, Suspected Limbic Predominant Age-related TDP-43 Encephalopathy (LATE)
- Trial name
- NCT06891716
- Testing
- [18F]ACI-19626
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Dementia, Alzheimer Disease
The Swedish BioFINDER 2 Study
The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g.
- Conditions
- Dementia, Alzheimer Disease, Parkinson Disease, Lewy Body Disease
- Trial name
- BioFINDER2 (NCT03174938)
- Testing
- Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau
- Where
- 2 sites in Sweden
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Alzheimer Disease, Dementia With Lewy Bodies (DLB)
Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder
This is a retrospective observational study to evaluate the clinical utility of blood-based biomarkers in the diagnosis and management of patients with a neurodegenerative disease (ND) or mental disorder (MD).
- Conditions
- Alzheimer Disease, Dementia With Lewy Bodies (DLB), Frontotemporal Dementia (FTD), Major Depressive Disorder (MDD)
- Trial name
- Synapsing-BK (NCT07314190)
- Where
- Spain
- Volunteers
- 1,799 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Progressive Supranuclear Palsy, Corticobasal Degeneration
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies
This is a phase II study intended to evaluate the safety, tolerability and pharmacodynamics of NIO752 in participants with primary tauopathies.
- Conditions
- Progressive Supranuclear Palsy, Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Tauopathies
- Trial name
- NCT07868328
- Testing
- NIO752
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Primary Progressive Aphasia, Dementia
Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia
Difficulties with speech and language are the first and most notable symptoms of primary progressive aphasia (PPA). While there is evidence that demonstrates positive effects of speech-language treatment for individuals with PPA…
- Conditions
- Primary Progressive Aphasia, Dementia, Dementia, Frontotemporal, Alzheimer Disease
- Trial name
- NCT05741853
- Testing
- Video-Implemented Script Training for Aphasia (VISTA), Lexical Retrieval Training (LRT)
- Where
- 3 sites in United States, Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Stephanie Grasso
Parkinson's Disease, Parkinsonism
Modifiable Variables in Parkinsonism (MVP)
We are trying to identify factors associated with improved quality of life and fewer PD symptoms. We are attempting to identify practices, beliefs, and therapies used by individuals who report excellent quality of life, few PD…
- Conditions
- Parkinson's Disease, Parkinsonism, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- NCT02194816
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Bastyr University
Alzheimer Disease, Dementia
DC Longitudinal Study on Aging and Specimen Bank
The Georgetown University Memory Disorders Program, part of the Department of Neurology, is conducting pilot studies of the feasibility of various diagnostic tests for Alzheimer's disease, mild cognitive impairment and other…
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment, Aging
- Trial name
- (DC LSOA) (NCT03702907)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Georgetown University
Alzheimer Disease, Frontotemporal Dementia
Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases
Double blinded, sham-controlled, randomized trial on repeated transcranial alternating current brain stimulation (tACS) in neurodegenerative diseases.
- Conditions
- Alzheimer Disease, Frontotemporal Dementia, Dementia With Lewy Bodies
- Trial name
- NCT05326750
- Testing
- Gamma tACS (40 Hz) over the superior parietal cortex
- Where
- Finland
- Volunteers
- 200 people
- Sponsor
- Kuopio University Hospital
Major Depressive Disorder (MDD), Schizophenia Disorder
Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers and Psychiatric Symptoms in Neurodegenerative Diseases and Mental Disorders
This is a prospective observational study to identify sociodemographic factors that predict mental health outcomes in the European population and provide evidence linking common, modifiable sociodemographic risk factors for…
- Conditions
- Major Depressive Disorder (MDD), Schizophenia Disorder, Bipolar 1 Disorder, Alzheimer Disease
- Trial name
- Synapsing-SD (NCT07239843)
- Where
- Spain
- Volunteers
- 1,310 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Primary Progressive Aphasia, Semantic Dementia
Primary Progressive Aphasia Multicomponent Language Treatment Study
The goal of this clinical trial is to learn if a speech-language telerehabilitation helps improve communication in people with primary progressive aphasia (PPA), a form of dementia that affects speech and language.
- Conditions
- Primary Progressive Aphasia, Semantic Dementia, Semantic Memory Disorder, Logopenic Progressive Aphasia
- Trial name
- NCT06649084
- Testing
- Multicomponent Lexical Retrieval Training (Multi-LRT), Multicomponent Video Implemented Script Training in Aphasia (Multi-VISTA), Multicomponent Communication Partner Training (Multi-CPT)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Texas at Austin
Alzheimer Disease, Mild Cognitive Impairment
BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers
This research study aims to examine biomarkers of Alzheimer's disease as early as possible which could potentially be a screening tool for the general population.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia
- Trial name
- NCT05457998
- Testing
- Flutemetamol F18 Injection, [18F]-RO6958948 Injection, [18F]-MK-6240 Injection
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Butler Hospital
Semantic Dementia
Revealing Engagement Dynamics Among Semantic Dementia Patients
The study intends to investigate the personal experiences of semantic dementia patients who take part in a separate clinical study including a specific medication intervention.
- Trial name
- NCT06218732
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.